Ann: 2023 AGM Chairman's Address and CEO Presentation, page-31

Thanks HT, I like that you are reporting Rohan's latest comment indicates 75 microgram will be the metric for a possible 4th cohort in Phase 1 (SAD).

I appreciate the update and it sounds like they have a healthy degree of conviction as to how high they wish to go whilst providing a level of confidence of a good outcome in humans based on the knowledge that a 50 microgram dose in monkeys, (with no adverse affects), correlates with up to a 100 microgram dose in a human eye.

75 microgram remains quite a significant increase when we consider the trial was originally approved for the following;
low = 3 microgram,
mid = 10 microgram
high = 30 microgram

I believe PYC are being very strategic